Office of Research & Development |
|
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX003688-01A1 |
| Title: | Dendritic Cell Proteoglycans and Reprogramming Cancer Immunity |
| Principal Investigator: | Mark M. Fuster |
| Location: | San Diego, CA |
| Congressional District Code: | 52 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | October 2017 - September 2021 |
| FY 2021 Funding Amount: | $165,000 |
| Total Award Amount (all years): |
$705,123 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Early in cancer growth, metastases and dendritic cells (DCs) traffic to draining lymph nodes (DLN). In lung cancer and other carcinomas, immune-suppression dominates a tumor microenvironment characterized by immature DCs, weak T-effector responses, proliferation of T-regulatory cells (Tregs), and over-production of immuno-suppressive cytokines. This heavily represses anti-tumor immunity. A high-impact area of new scientific discovery is immunotherapy. We find dramatic clinical responses in some... |